BTX-A
Small molecule
BTX-A is one of 16 small molecule programs targeting Hyperhidrosis. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Hyperhidrosis
#DrugCompanyPhaseTrials
1Oxytrol
WWim Janssens
Approved
Botulinum Toxin a
GSKApproved
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
GSK1358820
GSKPhase 3
Botox
RRevance Therapeutics, Inc.
Phase 2
Meditoxin
MMedy-Tox
Phase 3
Botox
AbbViePhase 2
Sofdra
BBotanix Pharmaceuticals
Phase 3
Glycopyrronium Bromide
NovartisPhase 2
Incruse Ellipta
GGlaxo Dba Glaxosmithkline
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BTX-A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- UUniversity of Wisconsin, Madison